SAN DIEGO, July 1, 2019 /PRNewswire/ -- Evofem Biosciences,
Inc. (NASDAQ: EVFM) (Evofem), a clinical-stage biopharmaceutical
company was added to the broad-market Russell
3000® Index and the small-cap Russell
2000® Index at the conclusion of the 2019 Russell
indexes annual reconstitution, effective at the U.S. market open on
July 1, 2019, according to a final
list of additions posted June 28.
"The inclusion of Evofem Biosciences in the Russell 3000 Index
is indicative of the company's significant progress and growth.
This momentum will escalate through 2019 as we advance our lead
investigational asset, Amphora®, a hormone-free, on
demand, first-in-class Multipurpose Vaginal pH Regulator (MVP-R™)
for birth control, toward NDA re-submission later this year and
potential approval in the second quarter of 2020," said
Saundra Pelletier, CEO of Evofem
Biosciences.
"In the United States, almost
half of women are not satisfied with their current birth control
method, reporting problems with side effects and reduced sexual
pleasure as main reasons for concern1, which has
resulted in unintended pregnancies costing the US government
$21 billion annually2.
With our investigational product Amphora, Evofem is seeking to put
power back in women's hands with protection on their terms. If
approved for marketing in the U.S., it will provide hormone-free
birth control, used only when she wants it."
Annual Russell indexes reconstitution captures the 4,000 largest
U.S. stocks as of May 10, ranking
them by total market capitalization. Membership in the U.S. all-cap
Russell 3000® Index, which remains in place for one
year, means automatic inclusion in the small-cap Russell
2000® Index as well as the appropriate
growth and value style indexes. FTSE Russell determines membership
for its Russell indexes primarily by objective,
market-capitalization rankings and style attributes.
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Approximately $9 trillion in assets are benchmarked against
Russell's US indexes. Russell indexes are part of FTSE Russell, a
leading global index provider.
For more information on the Russell 3000® Index and
the Russell indexes reconstitution, go to the "Russell
Reconstitution" section on the FTSE Russell website.
About Evofem Biosciences
Evofem Biosciences, Inc., is
a clinical-stage biopharmaceutical company committed to developing
and commercializing innovative products to address unmet needs in
women's sexual and reproductive health. The Company is leveraging
its proprietary investigational Multipurpose Vaginal pH Regulator
(MVP-R™) platform to develop Amphora® (L-lactic acid,
citric acid and potassium bitartrate). Amphora is designed to
regulate vaginal pH within the normal range of 3.5 to 4.5. This
maintains an acidic environment which is inhospitable to sperm as
well as certain viral and bacterial pathogens associated with STIs
but is integral to the survival of healthy bacteria in the vagina.
Evofem plans to resubmit the Amphora New Drug Application (NDA) for
hormone-free, woman-controlled birth control in the fourth quarter
of 2019. The investigational, first-in-class MVP-R is also in
development to prevent urogenital acquisition of certain sexually
transmitted infections.
For more information, please visit www.evofem.com.
NOTE: Amphora® is a registered trademark and MVP-R™
is a trademark of Evofem Biosciences, Inc.
1 Guttmacher Institute (2008): Improving
Contraceptive Use in the United
States
2 Guttmacher Institute (2015): Unintended Pregnancies
Cost Federal and State Governments $21
Billion In 2010
About FTSE Russell
FTSE Russell is a global index
leader that provides innovative benchmarking, analytics and data
solutions for investors worldwide. FTSE Russell calculates
thousands of indexes that measure and benchmark markets and asset
classes in more than 70 countries, covering 98% of the investable
market globally.
FTSE Russell index expertise and products are used extensively
by institutional and retail investors globally. Approximately
$16 trillion is currently benchmarked
to FTSE Russell indexes. For over 30 years, leading asset owners,
asset managers, ETF providers and investment banks have chosen FTSE
Russell indexes to benchmark their investment performance and
create ETFs, structured products and index-based derivatives.
A core set of universal principles guides FTSE Russell index
design and management: a transparent rules-based methodology is
informed by independent committees of leading market participants.
FTSE Russell is focused on applying the highest industry standards
in index design and governance and embraces the IOSCO Principles.
FTSE Russell is also focused on index innovation and customer
partnerships as it seeks to enhance the breadth, depth and reach of
its offering.
FTSE Russell is wholly owned by London Stock Exchange Group.
For more information, visit www.ftserussell.com
Forward-Looking Statements
This press release contains
"forward-looking statements" within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995,
including statements related to the timing of the planned Amphora
NDA re-submission for prevention of pregnancy, potential FDA
approval of Amphora, and the potential commercial launch of
Amphora. Each of these forward-looking statements involves
risks and uncertainties. Actual results may differ materially from
those, express or implied, in these forward-looking statements.
Important factors that could impair the value of Evofem
Biosciences' assets and business are disclosed in the risk factors
contained in its Annual Report on Form 10-K filed with the
Securities and Exchange Commission and subsequent filings. All
forward-looking statements are expressly qualified in their
entirety by such factors. Evofem Biosciences does not undertake any
duty to update any forward-looking statement except as required by
law.
Contacts
|
|
For Evofem
Biosciences
|
|
Investor
Relations
|
Media
|
Amy
Raskopf
|
Greg
Jawski
|
Evofem Biosciences,
Inc.
|
Porter
Novelli
|
araskopf@evofem.com
|
Greg.jawski@porternovelli.com
|
M: (917)
673-5775
|
M: (917)
749-4964
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/evofem-biosciences-added-to-russell-3000-index-300878276.html
SOURCE Evofem Biosciences, Inc.